It is estimated that the human genome encodes 15% of proteins that are considered to be disease-modifying. Only 2% of these proteins possess a druggable site that is approved as clinical candidate targets. Due to this disparity, there is an immense need to develop therapeutics that may better mitigate the diseases or disorders aroused by non-druggable and druggable proteins or enzymes. The recent surge in approved oligonucleotide therapeutics offers great potential for the treatment of these diseases or disorders.
As a dynamic pharmaceutical company in a vibrant life science research region, Alfa Chemistry leverages the expertise and experience of highly skilled, multi-disciplinary staff to provide development services for oligonucleotide therapeutics, including therapeutic ASO, siRNA, miRNA, aptamer, CpG oligonucleotide, DNAzyme, and transcription factor (TF) decoy. Our services primarily include target selection, sequence design, chemical synthesis, chemical modification, drug delivery, and non-clinical evaluation of oligonucleotide therapeutics. Our goal is to help you develop new oligonucleotide therapeutics and successfully bring them to market by optimizing existing methods or developing innovative technologies, benefitting patients worldwide. If you are also interested in the development of oligonucleotide therapeutics, please click on the link to learn more about our services. Let us work together to create a better world.
